Cellectar Biosciences, Inc. (NASDAQ:CLRB), shares were dipping -22.38% to $2.15 in the after-hours session on Tuesday after the company, focused on the discovery, development and commercialization of new cancer therapies, Cellectar Biosciencesannounced that it plans to offer and sell shares of its common stock and its common stock equivalents in a public offering. There is no guarantee as to whether the offering will be completed, or as to the size or terms of the offering, since it is subject to market conditions.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Upon completion of the public offering, the Company expects to sell shares of common stock and convertible preferred stock at the public offering price to certain investors in a private placement.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Read More
Oppenheimer & Co. Inc. is acting solely as an underwriter in the public offering.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Under the shelf registration statement previously filed with, and declared effective by, the Securities and Exchange Commission (SEC) on August 20, 2020, Cellectar will issue shares of common stock and common stock equivalents in the public offering. Only the prospectus and it’s supplement will be distributed in connection with this offering. With the Securities and Exchange Commission (SEC), the Company will file an initial prospectus supplement and an accompanying prospectus relating to the public offering. Additional copies of the preliminary prospectus supplement and accompanying prospectus may be obtained by contacting Oppenheimer & Co. Inc. at 85 Broad Street, 26th Floor, New York, NY, 10004, or by emailing EquityProspectus@opco.com.
